Treatment of Parkinson's disease

Clarke, 1995, Does levodopa therapy delay death in Parkinson’s disease? A review of the evidence, Movement Disorders, 10, 250, 10.1002/mds.870100303 Hely, 1999, The Sydney multicentre study of Parkinson’s disease: progression and mortality at 10 years, J Neurol Neurosurg Psychiatry, 67, 300, 10.1136/jnnp.67.3.300 Curtis, 1984, Effect of L-dopa on course of Parkinson’s disease, Lancet, ii, 211, 10.1016/S0140-6736(84)90493-8 Agid, 1998, Levodopa. Is Toxicity a myth?, Neurology, 50, 858, 10.1212/WNL.50.4.858 Hely, 1994, The Sydney Multicentre Study of Parkinson’s disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa, J Neurol Neurosurg Psychiatry, 57, 903, 10.1136/jnnp.57.8.903 Blin, 1988, Does levodopa aggravate Parkinson’s disease?, Neurology, 38, 1410, 10.1212/WNL.38.9.1410 Caraceni, 1991, The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression, Neurology, 41, 380, 10.1212/WNL.41.3.380 Obeso, 1994, The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson’s disease, Eur J Neurosci, 6, 889, 10.1111/j.1460-9568.1994.tb00584.x Bonnet, 1987, Does long-term aggravation of Parkinson’s disease result from nondopaminergic lesions?, Neurology, 37, 1539, 10.1212/WNL.37.9.1539 Mena, 1997, Glia protect fetal midbrain dopamine neurons in culture from L-DOPA toxicity through multiple mechanisms, J Neural Transm, 104, 317, 10.1007/BF01277654 Fahn, 1996, Is levodopa toxic?, Neurology, 47, S184, 10.1212/WNL.47.6_Suppl_3.184S Diamond, 1987, Multicentre study of Parkinson Mortality with early versus later dopa treatment, Ann Neurol, 22, 8, 10.1002/ana.410220105 Scigliano, 1990, Mortality associated with early and late levodopa therapy initiation in Parkinson’s disease, Neurology, 40, 265, 10.1212/WNL.40.2.265 Rajput, 1997, Timely levodopa (LD) administration prolongs survival in Parkinson’s disease, Parkinsonism Relat Disord, 3, 159, 10.1016/S1353-8020(97)00030-8 Murer, 1998, Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with mderate nigrostriatal lesions, Ann Neurol, 43, 561, 10.1002/ana.410430504 Fahn, 1998, Welcome news about levodopa, but uncertainty remains, Ann Neurol, 43, 551, 10.1002/ana.410430502 Ward, 1994, Does selegiline delay progression of Parkinson’s disease? A critical re-evaluation of the DATATOP study, J Neurol, Neurosurg, Psych, 57, 217, 10.1136/jnnp.57.2.217 Lees, 1995, Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early mild Parkinson’s disease, BMJ, 311, 1602, 10.1136/bmj.311.7020.1602 Olanow, 1996, Selegiline and mortality in Parkinson’s disease, Ann Neurol, 40, 841, 10.1002/ana.410400605 1998, Ann Neurol, 43, 318, 10.1002/ana.410430309 Yamomoto, 1998, Do dopamine agonists provide Neuroprotection?, Neurology, 51(Suppl 2), S10, 10.1212/WNL.51.2_Suppl_2.S10 Olanow, 1995, The effect of deprenyl and levodopa on the progression of Parkinson’s disease, Ann Neurol, 38, 771, 10.1002/ana.410380512 Lange, 1997, Dopamine/glutamate interactions in Parkinson’s disease, Neurosci Biobehav Rev, 21, 393, 10.1016/S0149-7634(96)00043-7 Rodriguez, 1998, Subthalamic nucleus-mediated excitotoxicity in Parkinson’s disease: a target for Neuroprotection, Ann Neurol, 44(Suppl 1), S175, 10.1002/ana.410440726 Olanow, 1996, Selegiline: current perspectives on issues related to Neuroprotection and mortality, Neurology, 47(Suppl 3), S210, 10.1212/WNL.47.6_Suppl_3.210S Schrag, 1998, Young-onset Parkinson’s disease revisited-clinical features, natural history, and mortality, Mov Disord, 13, 885, 10.1002/mds.870130605 Hoehn, 1967, Parkinsonism: onset, progression and mortality, Neurology, 17, 427, 10.1212/WNL.17.5.427 Block, 1997, Comparison of immediate-release and controlled-release carbidopa/levodopa in Parkinson’s disease: a multicentre 5 year study, Eur Neurol, 37, 23, 10.1159/000117399 Pfützner, 1997, Malignant melanoma and levodopa: Is there a relationship? Two new cases and a review of the literature, J Am Acad Dermatol, 37, 332, 10.1016/S0190-9622(97)80385-4 Weiner, 1993, Levodopa, melanoma, and Parkinson’s disease, Neurology, 43, 674, 10.1212/WNL.43.4.674 Factor, 1999, Dopamine agonists, Med Clinics North America, 83, 415, 10.1016/S0025-7125(05)70112-7 Montastruc, 1994, A randomised control study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson’s disease: a five year follow up, J Neurol Neurosurg Psych, 57, 1034, 10.1136/jnnp.57.9.1034 Rinne, 1998, Early treatment of Parkinson’s disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial, Drugs, 55 (Suppl 1), 23, 10.2165/00003495-199855001-00004 Rascol, 1999, Ropinirole reduces risk of dyskinesia when used in early Parkinson’s disease, Parkinsonism Relat Disord, 5, S83 1993, BMJ, 307 Bergamasco, 1990, Long-term bromocriptine treatment of de novo patients with Parkinson’s disease. A seven-year follow-up study, Acta Neurol Scand, 81, 383, 10.1111/j.1600-0404.1990.tb00980.x Rascol, 1998, Ropinirole in the treatment of early Parkinson’s disease: a 6-month interim report of a 5-year levodopa-controlled study, Mov Disord, 13, 39, 10.1002/mds.870130111 Shannon, 1997, Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease, Neurology, 49, 724, 10.1212/WNL.49.3.724 Korczyn, 1999, A comparison of ropinirole and bromocriptine in the treatment of early Parkinson’s disease for 3 years, Neurology, 53, 364, 10.1212/WNL.53.2.364 Carrion, 1998, A three and a half year experience with pramipexole (PMPX) monotherapy in patients with early Parkinson’s disease, Neurology, 50, A330 Pezzoli, 1995, A crossover controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson’s disease, Neurology, 45, S22, 10.1212/WNL.45.3_Suppl_3.S22 Guttman, 1997, Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease, Neurology, 49, 1060, 10.1212/WNL.49.4.1060 Inzelberg, 1996, Double-blind comparison of cabergoline and bromocriptine in Parkinson’s disease patients with motor fluctuations, Neurology, 47, 785, 10.1212/WNL.47.3.785 Frucht, 1999, Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole, Neurology, 52, 1908, 10.1212/WNL.52.9.1908 Goetz, 1985, Chronic agonist therapy for Parkinson’s disease: a five-year study of bromocriptine and pergolide, Neurology, 35, 749, 10.1212/WNL.35.5.749 Goetz, 1999, Switching dopamine agonists in advanced Parkinson’s disease, Neurology, 52, 1227, 10.1212/WNL.52.6.1227 Calne, 1993, Treatment of Parkinson’s disease, N Engl J Med, 329, 1021, 10.1056/NEJM199309303291408 Hely, 1996, An Australian multicentre open label study of pergolide as an adjunct to levodopa in Parkinson’s disease, J Clin Neuroscience, 3, 234, 10.1016/S0967-5868(96)90056-9 Lieberman, 1998, A multicentre trial of ropinirole as adjunct treatment for Parkinson’s disease, Neurology, 51, 1057, 10.1212/WNL.51.4.1057 Olanow, 1994, A multicentre double-blind placebo controlled trial of pergolide as an adjunct to sinemet in Parkinson’s disease, Mov Disord, 9, 40, 10.1002/mds.870090107 Kurth, 1998, COMT inhibition: a new treatment strategy for Parkinson’s disease, Neurology, 50 (Suppl 5), S3, 10.1212/WNL.50.5_Suppl_5.S3 Rajput, 1997, Tolcapone improves motor function in Parkinsonian patients with “wearing-off” phenomenon: a double-blind, placebo-controlled, multicentre trial, Neurology, 49, 1066, 10.1212/WNL.49.4.1066 Rinne, 1998, Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations, Neurology, 51, 1309, 10.1212/WNL.51.5.1309 1997, Ann Neurol, 42, 747, 10.1002/ana.410420511 1996, Australian Adverse Drug Reactions Bulletin, 15, 10 Djaldetti, 1996, Effect of subcutaneous administration of levodopa ethyl ester, a soluble prodrug of levodopa, on dopamine metabolism in rodent striatum: implication for treatment of Parkinson’s disease, Clin Neuropharmacol, 19, 65, 10.1097/00002826-199619010-00005 Morris, 1996, Stride length regulation in Parkinson’s disease. Normalization strategies and underlying mechanisms, Brain, 119 (Pt 2), 551, 10.1093/brain/119.2.551 Hughes, 1993, Subcutaneous apomorphine in Parkinson’s disease: response to chronic treatment for up to five years, Mov Disord, 8, 165, 10.1002/mds.870080208 Frankel, 1990, Subcutaneous apomorphine in the treatment of Parkinson’s disease, J Neurol Neurosurg Psychiatry, 53, 96, 10.1136/jnnp.53.2.96 Poewe, 1993, Continuous subcutaneous apomorphine infusions for fluctuating Parkinson’s disease. Long-term follow-up in 18 patients, Adv Neurol, 60, 656 Colzi, 1998, Continuous subcutaneous waking day apomorphine in the long-term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease, J Neurol Neurosurg Psychiatry, 64, 573, 10.1136/jnnp.64.5.573 Verhagen Metman, 1998, Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson’s disease, Neurology, 50, 1323, 10.1212/WNL.50.5.1323 Bushmann, 1989, Swallowing abnormalities and their response to treatment in Parkinson’s disease, Neurology, 39, 1309, 10.1212/WNL.39.10.1309 Poewe, 1999, Depression in Parkinson’s disease. Impediments to recognition and treatment options, Neurology, 52 (Suppl 3), S2 Leo, 1996, Movement disorders associated with the serotonin selective reuptake inhibitors, J Clin Psychiatry, 57, 449, 10.4088/JCP.v57n1002 Richard, 1997, Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease, Neurology, 48, 1070, 10.1212/WNL.48.4.1070 Hauser, 1997, Sertraline for the treatment of depression in Parkinson’s disease, Mov Disord, 12, 756, 10.1002/mds.870120522 Trosch, 1998, Clozapine use in Parkinson’s disease: a retrospective analysis of a large multicentered clinical experience, Mov Disord, 13, 377, 10.1002/mds.870130302 Friedman, 1998, Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson’s disease, Neurology, 50, 1195, 10.1212/WNL.50.4.1195-a Ford, 1994, Risperidone in Parkinson’s disease, Lancet, 344, 681, 10.1016/S0140-6736(94)92114-8 Mayeux, 1990, An estimate of the incidence of dementia in idiopathic Parkinson’s disease, Neurology, 40, 1513, 10.1212/WNL.40.10.1513 Reid, 1996, A longitudinal study of Parkinson’s disease: clinical and neuropsychological correlates of dementia, Journal of Clinical Neuroscience, 3(4), 327, 10.1016/S0967-5868(96)90028-4 Lang, 1999, Attempting to predict response to pallidotomy, Mov Disord, 13 (Suppl 2), 263 Charles, 1999, Preoperative indicators of clinical outcome following bilateral subthalamic nucleus stimulation for the treatment of Parkinson’s disease, Neurology, 52 (Suppl 2), A272 Baron, 1996, Treatment of advanced Parkinson’s disease by posterior GPi pallidotomy: 1-year results of a pilot study [see comments], Ann Neurol, 40, 355, 10.1002/ana.410400305 Dogali, 1995, Stereotactic ventral pallidotomy for Parkinson’s disease, Neurology, 45, 753, 10.1212/WNL.45.4.753 Samuel, 1998, A study of medial pallidotomy for Parkinson’s disease: clinical outcome, MRI location and complications, Brain, 121, 59, 10.1093/brain/121.1.59 Scott, 1998, Neuropsychological, neurological and functional outcome following pallidotomy for Parkinson’s disease. A consecutive series of eight simultaneous bilateral and twelve unilateral procedures, Brain, 121, 659, 10.1093/brain/121.4.659 Shannon, 1998, Stereotactic pallidotomy for the treatment of Parkinson’s disease. Efficacy and adverse effects at 6 months in 26 patients, Neurology, 50, 434, 10.1212/WNL.50.2.434 Lang, 1997, Posteroventral medial pallidotomy in advanced Parkinson’s disease [see comments], N Engl J Med, 337, 1036, 10.1056/NEJM199710093371503 Krack, 1999, Surgical treatment of Parkinson’s disease, Curr Opin Neurol, 12(4), 417, 10.1097/00019052-199908000-00008 Lang, 1997, Posteroventral medial pallidotomy in advanced Parkinson’s disease, N Engl J Med, 337, 1036, 10.1056/NEJM199710093371503 Ardouin, 1999, Bilateral subthalamic or pallidal stimulation for Parkinson’s disease affects neither memory nor executive functions: A consecutive of series of 62 patients, Ann Neurol, 46(2), 217, 10.1002/1531-8249(199908)46:2<217::AID-ANA11>3.0.CO;2-Z Trepanier, 1998, Neuropsychological consequences of posteroventral pallidotomy for the treatment of Parkinson’s disease, Neurology, 51, 207, 10.1212/WNL.51.1.207 Soukup, 1997, Cognitive sequelae of unilateral posteroventral pallidotomy, Arch Neurol, 54, 947, 10.1001/archneur.1997.00550200015004 Vingerhoets, 1999, Cognitive outcome after unilateral pallidal stimulation in Parkinson’s disease, J Neurol Neurosurg Psychiatry, 66, 297, 10.1136/jnnp.66.3.297 Hariz, 1999, Current controversies in pallidal surgery, Adv Neurol, 80, 593 Bronstein, 1999, Stereotactic pallidotomy in the treatment of Parkinson disease: an expert opinion, Arch Neurol, 56, 1064, 10.1001/archneur.56.9.1064 Laitinen, 1995, Pallidotomy for Parkinson’s disease, Neurosurg. Clin N Am, 6, 105, 10.1016/S1042-3680(18)30479-0 Kimber, 1999, Voluntary movement after pallidotomy in severe Parkinson’s disease, Brain, 122, 895, 10.1093/brain/122.5.895 Limousin, 1999, The effects of posteroventral pallidotomy on the preparation and execution of voluntary hand and arm movements in Parkinson’s disease, Brain, 122, 315, 10.1093/brain/122.2.315 Fung, 1996, A prospective study of posteroventral pallidotomy in the treatment of Parkinson’s disease, J Clin Neurosci, 3, 395 Johansson, 1997, Usefulness of pallidotomy in advanced Parkinson’s disease, J Neurol Neurosurg Psychiatry, 62, 125, 10.1136/jnnp.62.2.125 Gross, 1999, Relationship of lesion location to clinical outcome following microelectrode-guided pallidotomy for Parkinson’s disease [see comments], Brain, 122, 405, 10.1093/brain/122.3.405 Krack, 1998, Opposite motor effects of pallidal stimulation in Parkinson’s disease, Ann Neurol, 43, 180, 10.1002/ana.410430208 Bejjani, 1998, Deep brain stimulation in Parkinson’s disease: opposite effects of stimulation in the pallidum, Mov Disord, 13, 969, 10.1002/mds.870130618 Limousin, 1998, Electrical stimulation of the subthalamic nucleus in advanced Parkinson’s disease, N Engl J Med, 339, 1105, 10.1056/NEJM199810153391603 Kumar, 1998, Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson’s disease, Neurology, 51, 850, 10.1212/WNL.51.3.850 Fraix, 1999, The effect of subthalamic nucleus stimulation on levodopa-induced dyskinesias in patients with Parkinson’s disease, Neurology, 52 (Suppl 2), A403 Ghika, 1999, Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson’s disease: neuropsychological and neurological side effects. Report of four cases and review of the literature, J Neurosurg, 91, 313, 10.3171/jns.1999.91.2.0313 Cook, 1998, Evolution of a surgical technique for posteroventral pallidotomy using CT/MRI fusion and intraoperative macrostimulation, J Clin Neurosci, 5, 20, 10.1016/S0967-5868(98)90196-5 Gill, 1997, Bilateral dorsolateral subthalamotomy for advanced Parkinson’s disease [letter], Lancet, 350, 1224, 10.1016/S0140-6736(05)63455-1 Guridi, 1997, The role of the subthalamic nucleus in the origin of hemiballism and parkinsonism: new surgical perspectives, Adv Neurol, 74, 235 Pahwa, 1997, High-frequency stimulation of the globus pallidus for the treatment of Parkinson’s disease, Neurology, 49, 249, 10.1212/WNL.49.1.249 Troster, 1997, Unilateral pallidal stimulation for Parkinson’s disease: neurobehavioral functioning before and 3 months after electrode implantation, Neurology, 49, 1078, 10.1212/WNL.49.4.1078 Ghika, 1998, Efficiency and safety of bilateral contemporaneous pallidal stimulation (deep brain stimulation) in levodopa-responsive patients with Parkinsons’s disease with severe motor fluctuations: a two year follow-up review, J Neurosurg, 89, 713, 10.3171/jns.1998.89.5.0713 Galvez-Jimenez, 1998, Pallidal stimulation in Parkinson’s disease patients with a prior unilateral pallidotomy, Can J Neurol Sci, 25, 300, 10.1017/S0317167100034314 Narabayashi, 1998, Stereotactic surgery and Parkinson’s disease, Stereotact Funct Neurosurg, 70, 114, 10.1159/000029606 Tasker, 1990, Thalamotomy, Neurosurg Clin N Am, 1, 841, 10.1016/S1042-3680(18)30776-9 Benabid, 1987, Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease, Appl Neurophysiol, 50, 344 Benabid, 1991, Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus, Lancet, 337, 403, 10.1016/0140-6736(91)91175-T Koller, 1997, High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor, Ann Neurol, 42, 292, 10.1002/ana.410420304 Limousin, 1999, Multicentre European study of thalamic stimulation in parkinsonian and essential tremor, J Neurol Neurosurg Psychiatry, 66, 289, 10.1136/jnnp.66.3.289 Lozano, 1998, Pallidotomy for tremor, Mov Disord, 13 Suppl 3, 107 Krack, 1998, Treatment of tremor in Parkinson’s disease by subthalamic nucleus stimulation, Mov Disord, 13, 907, 10.1002/mds.870130608 DeLong, 1990, Primate models of movement disorders of basal ganglia origin, Trends Neurosci, 13, 281, 10.1016/0166-2236(90)90110-V Hutchison, 1998, Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson’s disease, Ann Neurol, 44, 622, 10.1002/ana.410440407 Hutchinson, 1997, Effects of apomorphine on globus pallidus neurons in parkinsonian patients, Ann Neurol, 42, 767, 10.1002/ana.410420513 Parent, 1998, The current model of basal ganglia organization under scrutiny, Mov Disord, 13, 199, 10.1002/mds.870130202 Chesselet, 1996, Basal ganglia and movement disorders: an update, Trends Neurosci, 19, 417, 10.1016/0166-2236(96)10052-7 Obeso, 1997, Basal ganglia pathophysiology. A critical review, Adv Neurol, 74, 3